MX2020008359A - Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. - Google Patents

Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.

Info

Publication number
MX2020008359A
MX2020008359A MX2020008359A MX2020008359A MX2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A
Authority
MX
Mexico
Prior art keywords
amino
carboxylic acid
difluoromethyliden
meniere
addiction
Prior art date
Application number
MX2020008359A
Other languages
English (en)
Spanish (es)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2020008359A publication Critical patent/MX2020008359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2020008359A 2018-02-08 2019-02-08 Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. MX2020008359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628020P 2018-02-08 2018-02-08
US201862628541P 2018-02-09 2018-02-09
PCT/US2019/017201 WO2019157273A1 (en) 2018-02-08 2019-02-08 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction

Publications (1)

Publication Number Publication Date
MX2020008359A true MX2020008359A (es) 2020-11-24

Family

ID=67475310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008359A MX2020008359A (es) 2018-02-08 2019-02-08 Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.

Country Status (10)

Country Link
US (1) US10653652B2 (https=)
EP (1) EP3735237A4 (https=)
JP (1) JP2021512920A (https=)
KR (3) KR20210007948A (https=)
CN (1) CN112261938A (https=)
AU (1) AU2019216742B2 (https=)
CA (1) CA3090258A1 (https=)
IL (1) IL276287A (https=)
MX (1) MX2020008359A (https=)
WO (1) WO2019157273A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061437T2 (hu) 2015-10-23 2023-06-28 Navitor Pharm Inc A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
US10912750B2 (en) 2017-04-26 2021-02-09 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
MX2020010302A (es) * 2018-03-29 2021-01-08 Ovid Therapeutics Inc Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
CA3156436A1 (en) * 2019-11-01 2021-05-06 Steven LEVENTER Methods of treatment using an mtorc1 modulator

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
EP1954316A1 (en) * 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20140315992A1 (en) 2011-07-07 2014-10-23 The Children's Hospital Of Philadelphia Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
EP2790686B1 (en) 2011-12-12 2021-03-10 Zilentin Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
EP2806867A4 (en) * 2012-01-27 2015-09-02 Catalyst Pharmaceutical Partners Inc METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
EP3341355B1 (en) 2015-10-09 2020-09-30 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma
EP4692048A3 (en) 2017-02-08 2026-04-01 Ovid Therapeutics Inc. Methods of treating cdkl5 disorders with the compound ov329

Also Published As

Publication number Publication date
KR20250167147A (ko) 2025-11-28
WO2019157273A1 (en) 2019-08-15
KR20240154700A (ko) 2024-10-25
EP3735237A4 (en) 2021-03-17
CA3090258A1 (en) 2019-08-15
JP2021512920A (ja) 2021-05-20
IL276287A (en) 2020-09-30
AU2019216742A1 (en) 2020-08-13
CN112261938A (zh) 2021-01-22
KR20210007948A (ko) 2021-01-20
US20190240174A1 (en) 2019-08-08
EP3735237A1 (en) 2020-11-11
AU2019216742B2 (en) 2024-05-09
US10653652B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
MX2020008359A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
MX2024010140A (es) Nuevos metodos.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
MX2022000143A (es) Metodos novedosos.
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
MX2020010469A (es) Inhibidores del atf6 y sus usos.
MX383932B (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
MX2022003128A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2018005983A2 (es) Compuestos de isoindol
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX394475B (es) Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
CL2019001918A1 (es) Métodos para tratar infecciones bacterianas.
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
EA201991488A1 (ru) Модуляторы калиевых каналов
MX2018013943A (es) Metodo de tratamiento de hiperglucemia.